Findings

What do systematic reviews say?

2 questions · 2 findings · 2 reviews · Schizophrenia

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 100%Moderate 0 · 0%High 0 · 0%

RISPERIDONE DEPOT vs OLANZAPINE

Adverse events: General ‐ serious · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in adverse events: General ‐ serious compared with ORAL OLANZAPINE (low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.1 [0.8, 1.51]
1 study · 547 participants
Low

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN vs CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐ medium term (3‐12 months)

Adverse events: 1a. Serious adverse event ‐ switching to aripiprazole · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems

SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN showed no clear difference in adverse events: 1a. Serious adverse event ‐ switching to aripiprazole compared with CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐… (low certainty).

1 finding from 1 review

Antipsychotic switching for people with schizophrenia who have neuroleptic‐induced weight or metabolic problems 2010 · Cochrane Headline outcomes only
RR 0.64 [0.24, 1.71]
1 study · 172 participants
Low